Nursing Elites

1. A healthcare professional is preparing to administer Belimumab for a client with Systemic Lupus Erythematosus. Which of the following actions should the healthcare professional plan to take?

• A. Warm the medication to room temperature before administering.
• B. Administer the medication by slow IV infusion over the recommended time frame.
• C. Dilute the medication in an appropriate solution as per manufacturer guidelines.
• D. Monitor the client for hypersensitivity reactions.

Correct answer: D

Rationale: The correct action the healthcare professional should plan to take when administering Belimumab is to monitor the client for hypersensitivity reactions. Belimumab is known to cause severe infusion reactions, including anaphylaxis in some cases. Monitoring for hypersensitivity reactions is crucial to detect and manage any adverse reactions promptly. Options A, B, and C are incorrect because warming the medication, administering by slow IV infusion, and dilution are not specific actions needed for Belimumab administration. The priority is to monitor the client for potential hypersensitivity reactions to ensure their safety.

2. Which of the following is not a side effect of loop diuretics?

• A. Alkalosis
• B. Nausea
• C. Hypotension
• D. Potassium deficits

Correct answer: B

Rationale: Nausea is not commonly associated with loop diuretics. Loop diuretics are known to cause electrolyte imbalances such as potassium deficits, metabolic alkalosis, and hypotension due to excessive fluid loss. Nausea is not a typical side effect of loop diuretics.

3. When assessing a client taking Lithium Carbonate for Bipolar disorder, which finding should the nurse recognize as a possible indication of toxicity to this medication?

• A. Severe hypertension
• B. Coarse tremors
• C. Constipation
• D. Muscle spasm

Correct answer: B

Rationale: The correct answer is B: Coarse tremors. Coarse tremors are a common sign of Lithium toxicity. Monitoring for tremors is crucial as they can indicate a potentially serious complication that requires immediate intervention. While other options such as severe hypertension, constipation, and muscle spasm may be symptoms of various conditions, they are not typically associated with Lithium toxicity. Severe hypertension is not a common sign of Lithium toxicity; constipation is not a typical symptom of Lithium toxicity either, and muscle spasm is not a direct indicator of Lithium toxicity.

4. A client has a new prescription for Digoxin. Which of the following instructions should the nurse include?

• A. Take the medication with food.
• B. Monitor your pulse before taking the medication.
• C. Expect to have an increased appetite.
• D. Discontinue the medication if you feel nauseated.

Correct answer: B

Rationale: When educating a client about Digoxin, it is crucial to instruct them to monitor their pulse before taking the medication. Digoxin can lead to bradycardia, so monitoring the pulse is essential to ensure it is not below 60 beats per minute before taking each dose. If the pulse is low, the client should hold the dose and seek guidance from their healthcare provider. Choices A, C, and D are incorrect. Taking Digoxin with food may affect its absorption, Digoxin is not known to increase appetite, and feeling nauseated does not necessarily indicate the need to discontinue the medication.

5. A client is starting therapy with docetaxel. Which of the following findings should the nurse instruct the client to report?

• A. Flushing
• B. Dyspnea
• C. Hyperglycemia
• D. Tinnitus

Correct answer: B

Rationale: The correct answer is B: Dyspnea. The nurse should instruct the client to report dyspnea because it can indicate pulmonary toxicity, a serious adverse effect of docetaxel. Dyspnea may be a sign of a potentially life-threatening condition that the healthcare provider needs to address promptly. Flushing (Choice A) is not typically associated with docetaxel therapy. Hyperglycemia (Choice C) is also not a common side effect of docetaxel. Tinnitus (Choice D) is not a usual finding with docetaxel and is not a priority over potential pulmonary toxicity indicated by dyspnea.

Similar Questions